Fenfluramine, a serotonin releaser and uptake inhibitor, has been widely prescribed as an appetite suppressant. Despite its popular clinical use, however, the precise neural pathways and specific 5-HT receptors that account for its anorectic effect have yet to be elucidated. To test the hypothesis that stimulation of 5-HT 1B receptors is required for the anorectic effect of fenfluramine, we assessed food intake in wild-type and 5-HT 1B knock-out mice. Next, to determine possible brain structures and pathways that may contribute to the 5-HT 1B -mediated effects of fenfluramine, we studied by immunohistochemistry the induction of the immediate early gene c-fos. Although the effect of fenfluramine on locomotion was indistinguishable between both wild-type and 5-HT 1B knock-out mice, the anorectic effect of the drug was absent in only the knock-out mice. Furthermore, the induction of c-Fos immunoreactivity found in the paraventricular nucleus of the hypothalamus (PVN) of wildtype mice was substantially reduced in the knock-outs. Induction in the central amygdaloid nucleus (CeA) and in the bed nucleus of the stria terminalis (BNST), although robust in wildtype animals, was completely absent in knock-out animals. The mixed 5-HT 1A/1B agonist RU24969 was able to mimic both the hypophagia and c-fos induction elicited by fenfluramine in wildtype mice, but not in the 5-HT 1B knock-out mice. Our results thus demonstrate that stimulation of 5-HT 1B receptors is required for fenfluramine-induced anorexia and suggest a role for the PVN, CeA, and BNST in mediating this effect.
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Obesity and associated pathologies, including diabetes and cardiovascular disease, are serious health concerns in developed countries (Garrow, 1991; Kuczmarski et al., 1994) . In recent years, there has been a substantial increase in both research and use of centrally acting appetite suppressants, which have been shown to facilitate weight loss and prevent weight regain in obese patients (Silverstone, 1992; Davis and Foulds, 1996) . The most popular and widely prescribed of these drugs had been fenfluramine, a serotonin releaser and uptake inhibitor (Guy-Grand, 1995) . Despite its popular clinical use, however, the precise neural pathways and specific 5-HT receptors that mediate its anorectic effect are not yet understood.
The diversity of 5-HT receptors and lack of specific antagonists have complicated attempts to elucidate the specific receptors involved in fenfluramine-induced hypophagia Simansky, 1996) . Studies with nonselective 5-HT antagonists have determined that the contributions of 5-HT 1A , 5-HT 2A , 5-HT 3 , and 5-HT 4 receptors are unlikely (Neill and Cooper, 1989; Vickers et al., 1996) . Attenuation of fenfluramine-induced hypophagia by the 5-HT 1A /1B antagonist cyanopindolol indicates that 5-HT 1B receptors may play a prominent role (Neill and Cooper, 1989; Grignaschi and Samanin, 1992; Grignaschi et al., 1995) . Experiments performed on 5-HT-depleted animals indicate that 5-HT 2C and yet unknown metergoline-sensitive receptors may also be critical (Gibson et al., 1993; Curzon et al., 1997) .
Several studies suggest that fenfluramine exerts its effects by acting through the paraventricular nucleus of the hypothalamus (PVN) (Leibowitz, 1992) . Microinjection of indirect 5-HT agonists fenfluramine and fluoxetine and 5-HT 1B direct agonists RU24969 and 1-[3-trifluoromethylphenyl]-piperazine into the PVN has been shown to elicit hypophagia (Hutson et al., 1988; Leibowitz et al., 1990; Weiss et al., 1990 Weiss et al., , 1991 . Lesioning the PVN, however, does not alter the hypophagic response elicited from systemic administration of the compounds (Fletcher et al., 1993) , indicating, therefore, that other hypothalamic nuclei and/or extrahypothalamic pathways may also contribute.
As an alternative to classic pharmacological approaches, mice lacking neurotransmitter receptors are useful tools for deciphering the specific receptors responsible for behavioral and physiological responses (Lucas and Hen, 1995) . We have generated mice lacking the 5-HT 1B receptor (Saudou et al., 1994) and have demonstrated the contribution of 5-HT 1B receptors in a variety of behaviors and physiological effects (Saudou et al., 1994; Crabbe et al., 1996; Ramboz et al., 1996; Yu et al., 1996; Brunner and Hen, 1997, Lucas et al., 1997; Rocha et al., 1998) . In this paper, using a food intake behavior paradigm, we show that the hypophagic effect of fenfluramine is absent in 5-HT 1B knock-out mice, indi-cating that stimulation of 5HT 1B receptors is required for this response.
Finally, to elucidate possible brain structures and pathways that contribute to the 5-HT 1B -mediated effects of fenfluramine, we examined immunoreactivity for c-fos, an immediate early gene whose induction in response to given stimuli can be used to map neuronal activation (Sagar et al., 1989; Morgan and Curran, 1991) . We show that fenfluramine elicits a reduced induction of c-fos in the PV N in knock-out animals, and that the central amygdaloid complex is a candidate extrahypothalamic brain region to mediate 5-HT 1B -and fenfluramine-induced anorexia.
MATERIALS AND METHODS

Animals.
All experiments were performed on adult wild-type and 5-HT 1B knock-out 129/Sv-ter inbred mice. The 5-HT 1B knock-out mice were generated as described previously (Saudou et al., 1994) . Both the wildtype and knock-out mice are bred at the New York State Psychiatric Institute animal facility and are identified by genomic Southern analyses of tail biopsies (Saudou et al., 1994) . Mice were housed four per cage with food and water available ad libitum and maintained in a temperaturecontrolled environment on a 12 hr light /dark cycle with light onset at 7:00 A.M. Immediately before testing, mice were housed individually, and water was maintained ad libitum.
Drug treatment. Fenfluramine hydrochloride [N-ethyl-a-methyl-m-(trifluoromethyl)phenylethylamine; Sigma, St. L ouis, MO] and RU24969 (generously supplied by Roussel-Uclaf, Romainville, France) were dissolved in 0.9% NaC l solution. Drugs were administered intraperitoneally in volumes of 1.0 ml / kg. Control animals were given an equivalent volume of the vehicle via the same route.
Feeding behavior paradigms. In all designs, food was given in pellet form and was provided in the food and water racks that are placed in each cage. The food form and the manner it was administered is the same for testing and for maintenance. Six to seven age-matched animals were used in each of the following groups: (1) for the baseline feeding response group, individually housed animals were given a preweighed quantity of chow, and the amount of food eaten was measured after 96 hr; and (2) for the feeding response to food deprivation group, mice were food-deprived, but not water-deprived, for 24 hr. Food was then readministered, and the amount of intake was measured after 20 min and 1, 4, and 24 hr. To determine the effect of drugs on feeding, an injection of drug (fenfluramine at 3 or 10 mg / kg or RU24969 at 5 mg / kg) or vehicle was given after the deprivation period. The above protocol was repeated 5 min after the injection of fenfluramine or 20 min after RU24969.
Locomotion paradigm. Testing was conducted between 8:00 A.M. and 5:00 P.M. Animals were placed in 20 ϫ 20 cm open-field chambers. They were monitored throughout the test session by a video-tracking system (PolyTrack; San Diego Instruments, San Diego, CA) that records the animal's location and path. It monitors up to four animals simultaneously through a video camera located above the open field that records each animal's position every 0.5 sec. The system is also equipped with infrared photo beams located 4 cm above the floor of the open field that record rearing events. Similarly, there are eight photocell-equipped holes located around the perimeter of the field that record nose poke events. Animals are also videotaped throughout all test sessions.
To habituate animals to the injection procedure and the open field, on the day before testing began the mice were given saline injections intraperitoneally and then monitored in the open field for 30 min. For drug testing, animals were brought to the testing room 1 hr before the test session began. Animals were injected with either fenfluramine or saline vehicle 10 min before the test session. Then, animals were placed directly in the open field and monitored continuously for 90 min. Data regarding each animal's path length, rearing, and nose poke behavior and the time spent in the center of the open field were collected and summed for each 5 min interval during the test session.
Immunohistochemistr y. Mice were administered drugs intraperitoneally. Food was not available to the animals at this time, but water was maintained ad libitum. T wo hours after drug administration, mice were anesthetized with a ketamine -Rompum mixture and perf used transcardially with 4% paraformaldehyde in 0.1 M PBS for 10 min. Brains were post-fixed in 4% paraformaldehyde for 2 hr at room temperature and then stored in PBS with 30% sucrose for 48 hr at 4°C. Coronal sections (30 m) were cut on a freezing microtome and collected in PBS with 0.3% sodium azide. Free-floating sections were pretreated with 3% H 2 O 2 in PBS and incubated overnight at 4°C in affinity-purified primary antibody raised against the c-fos N-peptide (AB-2; Oncogene Sciences, Mineola, N Y) diluted 1:500 in PBS containing 0.3% Triton X-100, 10% normal goat serum (Life Technologies, Gaithersburg, MD), and 1% BSA (Boehringer Mannheim, Indianapolis, I N). Sections were then rinsed and carried through standard avidin -biotin immunohistochemical protocols using an Elite Vectastain kit (Vector Laboratories, Burlingame, CA). Chromogen reaction was performed with 3,3-diaminobenzidine tetrahydrochloride (Sigma, St L ouis, MO) and 0.003% H 2 O 2 for 10 min. The sections were mounted on chromalum-coated slides and coverslipped with Aqua-PolyMount (Polysciences, Warrington, PA). Omission of the primary antibody or preabsorption with the N-peptide (Oncogene Sciences, Mineola, N Y) resulted in absence of labeling.
Cell counting. Counting of the number of immunopositive nuclei was performed using a computerized image analysis system (MCI D; Imaging Research) attached to a microscope (Diaplan; Leica, Nussloch, Germany). The counting was performed in a semiautomated manner with shading error acquired in a nonsample containing part of the preparation to correct for uneven distribution of light and form and shape factors suitable for the used magnification. Analysis was done on multiple sections per brain spanning each brain region examined.
Data anal ysis. Mean amount of food eaten after drug administration was compared using one-and two-way ANOVA with food eaten after 1, 4, and 24 hr as a repeated measure. Post hoc comparisons were made using Scheffé analysis. Similarly, mean locomotion was analyzed by a one-way ANOVA using activity in each successive 5 min interval as a repeated measure. Mean c-Fos positive nuclei per brain were analyzed via an unpaired t test. All calculations were done using the Statview 4.0 program (Abacus Concepts, C alabasas, CA).
RESULTS
Mice lacking the 5-HT 1B receptor do not differ from wild-type mice in body weight or baseline food intake
Body weight was compared between wild-type and knock-out mice at different ages (from early postnatal to 24 weeks). No significant difference was seen at any age. For example, at 20 weeks wild-type mice weighed 33.3 Ϯ 0.6 gm (n ϭ 22), whereas the knock-out mice weighed 33.4 Ϯ 0.5 gm (n ϭ 20). Next, the baseline feeding response of the two groups was monitored over a 96 hr period in free-feeding, individually housed animals. Again, no significant difference was detected (Fig. 1 A) . Similarly, after a 24 hr period of food deprivation, the amount of food intake after 20 min (data not shown) and 1, 4, and 24 hr also indicated no detectable difference between wild-type and knockout animals (Fig. 1 B) .
Mice lacking the 5-HT 1B receptor display no hypophagia after fenfluramine administration
The possible role of the 5-HT 1B receptors was explored by comparing the effect of fenfluramine in feeding behavior of wild-type and 5-HT 1B knock-out mice. After a 24 hr food deprivation period, both groups were administered saline or a 3 or 10 mg/kg dose of fenfluramine. A preweighed quantity of pellets was made available 5 min after drug administration, and food intake was measured after 1, 4, and 24 hr. The response after fenfluramine administration differed between the two groups over time. ANOVA revealed a significant interaction between genotype and dose (Fig. 2) . In agreement with previous findings (Shukla et al., 1990) , a 10 mg/kg dose of fenfluramine significantly reduced food intake in wild-type animals when compared with saline at hours 1 and 4. An intermediate dose of 3 mg/kg was sufficient to induce this anorectic effect to a similar degree. In sharp contrast to the wild type, both 3 and 10 mg/kg fenfluramine failed to reduce food intake in the 5-HT 1B knock-outs at all times studied. By hour 24, fenfluramine-treated wild-type animals ate similar amounts to control at both doses (data not shown).
The 5-HT 1A/1B mixed agonist RU24969 fails to elicit a hypophagic response in 5-HT 1B knock-out mice Food intake of food-deprived wild-type and knock-out mice after administration of 5 mg / kg 5-HT 1A /1B agonist RU24969 was determined (Fig. 3) . A strong interaction between genotype and dose was again revealed via ANOVA. RU24969 caused a sharp decrease in food intake over a 4 hr period in wild-type mice when compared with saline-injected counterparts. The 5-HT 1B knockouts, however, showed no significant decrease in food intake in response to RU24969. The anorectic effect of RU24969 in wildtype mice and its absence in knock-out mice is in agreement with the reported ability of 5-HT 1B agonists to decrease food intake in rats (Kennett et al., 1987; Kennett and Curzon, 1988; Lee and Simansky, 1997) .
Feeding response is independent of locomotor effect of fenfluramine 5-HT 1B agonists are known to increase locomotion (Oberlander et al., 1986; Cheetham and Heal, 1993) . On the contrary, fenfluramine has been reported to decrease locomotion in rats (Callaway et al., 1993) . We thus reasoned that a difference between wild-type and knock-out mice in baseline locomotor activity or in the effect of fenfluramine on locomotion might contribute to the difference found in the food intake paradigm. To address this, we compared the locomotor effect of fenfluramine in these mice. On the testing day, mice were given saline vehicle or 3 or 10 mg/kg fenfluramine intraperitoneally and monitored in an open field for 60 min. Data were collected every 0.5 sec and summed to 5 min intervals. As reported previously (Saudou et al., 1994) , wild-type and knock-out mice did not differ in baseline locomotor behavior (Fig. 4) . As in rats, fenfluramine decreased locomotion in mice in a dose-dependent manner. Importantly, the hypolocomotor effect in the 5-HT 1B knock-outs was indistinguishable from the wild type, thus demonstrating that the difference seen in feeding is not attributable to a drug-induced change in locomotion. Exploratory parameters, such as rearings and nose pokes, also revealed a dose-dependent decrease attributable to fenfluramine, and no significant difference was seen between genotypes (data not shown).
Fenfluramine-induced Fos-like immunoreactivity in PVN requires 5-HT 1B receptor activation
The PVN has been suggested to play a crucial role in 5-HTinduced anorexia. This is further supported by the reported ability of fenfluramine, as well as endogenous satiety inducers such as cholecystokinin and 2-buten-4-olide, to activate c-Fos in this brain region (Verbalis et al., 1991; Li and Rowland, 1993; Hisano et al., 1994) . To test whether stimulation of 5-HT 1B receptors is required for this effect of fenfluramine, we compared the level of c-Fos immunoreactivity in the PVN after fenfluramine administration (Fig. 5) .
Although administration of saline produces virtually no c-Fospositive signal in the PVN of both wild-type and 5-HT 1B knockout animals (Fig. 5A) , a 10 mg/kg injection of fenfluramine produces a robust c-Fos signal in the PVN of wild-type animals (Fig. 5B) . The signal induced in the 5-HT 1B knock-outs, however, was markedly reduced (Fig. 5C) .
We then tested whether stimulation of 5-HT 1B receptor with the direct agonist RU24969 would also be able to induce c-Fos in the PVN. A 5 mg/kg injection of RU24969 produced results similar to fenfluramine. In the wild-type mouse, RU24969 induced a robust signal in the PVN, whereas virtually no signal was present in the knock-out (Fig. 6) . Because the induction is absent in the knock-out, it appears that RU24969 induces c-Fos through its 5-HT 1B agonist effect and not via activation of 5-HT 1A receptors.
Central amygdaloid complex is a candidate brain region to mediate 5-HT 1B -and fenfluramine-induced anorectic effect
In an attempt to identify extrahypothalamic regions that may contribute to the hypophagic effect of these compounds, we compared the Fos levels in brain regions in which fenfluramine has been shown to induce c-Fos. Among these structures are the central nucleus of the amygdala (CeA), the bed nucleus of stria terminalis (BNST), the midline thalamic nuclei, and the striatum (Richard et al., 1992; Li and Rowland, 1993) .
In agreement with previous findings in rats (Li and Rowland 1993) , a 10 mg/kg dose of fenfluramine induced c-fos in all of these brain regions in wild-type mice (Fig. 7) (data not shown). In contrast, virtually no induction was seen in the CeA and BNST of the knock-out mice (Fig. 7C, F ) , although the induction found in the midline thalamic nuclei and the striatum showed little, if any, difference (data not shown). These results suggest that the reduced induction in knock-out PVN, CeA, and BNST is specific and not attributable to abnormal pharmacokinetic properties of fenfluramine in the knock-out mice.
We then tested whether a 5 mg/kg dose of RU24969 would be able to mimic the induction of c-Fos elicited by fenfluramine. RU24969 also induced c-Fos immunoreactivity in both the CeA and BNST of wild-type mice (data not shown). Again, this effect was absent in the knock-out mice, thus pointing to a mediation by 5-HT 1B receptors.
DISCUSSION
Using mice lacking the 5-HT 1B receptor, we show that fenfluramine does not induce hypophagia in these mice, thus indicating that activation of the 5-HT 1B receptor is necessary for this response. Furthermore, by examining the c-Fos induction in different brain regions, we find that there is robust induction in the PVN, the C eA, and BNST of wild type, whereas partial to no induction was found in the knock-outs. The C eA and BNST, therefore, are potential extrahypothalamic brain regions that may contribute to the effects of fenfluramine. Our results indicating that 5-HT 1B receptors play an important role for the anorectic effect of fenfluramine do not contradict those suggesting that stimulation of 5-HT 2C also contributes (for review, see Garattini et al., 1989; Dourish, 1992) . Although there has been controversy as to whether stimulation of 5-HT 2C reduces food intake or simply the rate of eating without affecting total food intake (for review, see Simansky, 1996) , it is possible that simultaneous and synergistic activation of 5-HT 1B and 5-HT 2C receptors are required to induce the full effect. The observation that c-fos induction by fenfluramine in the PVN is reduced but not absent in the knock-out, concurrently with the reported ability of the 5-HT 2A /2C agonist 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane to induce Fos in the PVN (Rouillard et al., 1996) , may reflect this synergism.
Recently, it has been hypothesized that the effect of fenfluramine might be attributable to direct activation of postsynaptic receptors while being independent of elevated synaptic 5-HT levels (Menini et al., 1991; Gibson et al., 1993; Curzon et al., 1997) . This hypothesis arises from the observation that the hy- Figure 2 . Mean Ϯ SEM food intake of wild types (white bars) and 5-HT 1B knock-outs (black bars) 1 and 4 hr after fenfluramine administration. Values on the x-axis indicate dose of fenfluramine (mg / kg). Drug was administered intraperitoneally after 24 hr of food deprivation. At hour 1, there was a main effect of genotype (F (1,34) ϭ 32.54; p Ͻ 0.0001), a main effect of dose (F (2,34) ϭ 15.30; p Ͻ 0.001), and an interaction of genotype by dose (F (2,34) ϭ 3.46; p Ͻ 0.05). At hour 4, there was a main effect of genotype (F (1,34) ϭ 15.19; p Ͻ 0.001) and an interaction of genotype by dose (F (2,34) ϭ 3.51; p Ͻ 0.05). Post hoc Scheffé analysis revealed that in wild types, fenfluramine significantly decreased food intake at both 3 and 10 mg/kg at hours 1 and 4. 5-HT 1B knock-outs, however, did not demonstrate any significant change in feeding at either dose. Asterisk s denote significant decreases in intake as compared with saline administration: *p Ͻ 0.01; **p Ͻ 0.005; ***p Ͻ 0.001. Figure 3 . Mean Ϯ SEM food intake of wild types (white bars) and 5-HT 1B knock-outs (black bars) after injection of the 5-HT 1A /1B mixed agonist RU 24969. Injections were given intraperitoneally after a 24 hr food deprivation period. ANOVA revealed an interaction of genotype by dose (F (1,20) ϭ 10.25; p Ͻ 0.005). A 5 mg / kg dose of RU 24969 significantly reduced the amount of food intake in wild types (**p Ͻ 0.005), whereas the anorectic effect was absent in knock-outs. The saline-injected groups were not significantly different. Figure 4 . Mean Ϯ SEM path length traversed by wild types (white bars) and 5-HT 1B knock-outs (black bars) in 5 min intervals after intraperitoneal administration of 0, 3, or 10 mg / kg fenfluramine. Habituated animals were monitored for 1 hr, 10 min after injection. Mean path length decreases in a dose-dependent manner after fenfluramine administration for wild types and 5-HT 1B knock-outs. ANOVA revealed a main effect of treatment (F (2,696) ϭ 21.51; p Ͻ 0.0001), whereas there was no effect of genotype (F (1,696) ϭ 0.009; p ϭ 0.9262) and no interaction between genotype and treatment (F (2,696) ϭ 0.003; p ϭ 0.9967).
pophagic effect of d-fenfluramine was not significantly affected by pretreatment with the inhibitor of 5-HT synthesis p-chlorophenylalanine ( p-C PA) (Gibson et al., 1993) . However, the lack of an effect by p-C PA may be explained by d-fenfluramine acting on p-C PA-resistant nerve terminals. In addition, a direct effect of fenfluramine on 5HT 1B receptors is unlikely, because fenfluramine and its metabolites display very low affinity for 5-HT 1B receptor sites (Menini et al., 1991) . Therefore, our findings, as well as the previously reported ability of cyanopindolol, a 5HT 1B antagonist, to antagonize fenfluramineinduced hypophagia (Neill and Cooper, 1989; Grignaschi and Samanin, 1992; Grignaschi et al., 1995) , cannot be explained in terms of direct activation of a postsynaptic receptor.
We have shown that activation of 5-HT 1B receptors either by the direct agonist RU24969 or the indirect agonist fenfluramine results in reduced food intake. One may therefore expect that disruption of the gene encoding the 5-HT 1B receptor would result in an abnormal control of appetite, and therefore, abnormal body weight. The 5-HT 1B knock-out mice, however, are indistinguishable from their wild-type littermates in body weight and total food intake over the test period. It is possible that compensations of other neurotransmitters and receptors involved in appetite control may have taken place to adjust for the absence of the 5-HT 1B receptor. An alternative explanation for the absence of a body weight phenotype is that 5-HT 1B receptors are not involved in the regulation of baseline feeding behavior. This may explain why attempts to antagonize the 5-HT 1B receptors by classic pharmacological means do little to this behavior (Blundell and Latham, 1980; Lee and C lifton, 1992) .
High densities of 5-HT 1B receptor binding sites have been reported in the PV N and C eA, whereas moderate levels have been reported in the BNST (Bruinvels et al., 1994) . Furthermore, these three brain regions receive a dense serotonergic innervation from raphe nuclei (Sawchenko et al., 1983; Ma et al., 1991; Alheid et al., 1995) . The c-Fos induction found in these regions can therefore be a direct consequence of activation of 5-HT 1B receptors located there. It cannot be ruled out, however, that stimulation of 5-HT 1B receptors in other brain regions triggers this induction through a polysynaptic mechanism. In fact, substantia nigra, the brain region with the highest level of 5-HT 1B receptor sites, sends projections to both the C eA and the BNST (Alheid et al., 1995) .
5-HT 1B receptors are localized on axon terminals (Waeber and Palacios, 1989; Boschert et al., 1993; Bruinvels et al., 1993; Stark et al., 1997) , where they have been shown to inhibit neurotransmitter release (Hoyer and Middlemiss, 1989; Johnson et al., 1992; Cameron and Williams, 1994; Hoyer et al., 1994) . We do not know the mechanisms through which stimulation of 5-HT 1B receptors located within and /or outside the PV N, C eA, and BNST results in induction of c-Fos. For the PV N, it is possible to speculate about potential mechanisms because its interconnections are relatively well known. The assumption that local 5-HT 1B receptors are involved is based on the observation that local application of 5-HT 1B agonists elicits hypophagia (Hutson et al., 1988) . The arcuate nucleus (ARC), the main source of neuropeptide Y containing afferents to the PVN (Morris, 1989) , contains one of the highest densities of 5-HT 1B receptor mRNA in the brain (Bruinvels et al., 1994) . It is therefore likely that at least a fraction of the 5-HT 1B receptors in the PVN are located on NPYergic terminals emanating from the ARC. It is likely that stimulation of 5HT 1B receptors located on these terminals will inhibit NPY release. Because NPY is a potent feeding inducer, a decrease in NPY levels as a consequence of 5-HT 1B receptor stimulation might account, at least in part, for the 5-HT 1B -related effects of fenfluramine reported here.
Unlike the PVN, however, the role of the central amygdaloid complex in feeding behavior and energy balance has not been fully explored. The central amygdaloid group includes the CeA and elements of the BNST (Alheid et al., 1995) . Moderate levels of 5HT 1B receptor mRNA have been found in this region (Bruinvels et al., 1994) . Interestingly, this region has been implicated in learned taste aversion (Borsini and Rolls, 1984) , and studies also indicate that this structure is involved in the control of food intake and energy balance (Weingarten et al., 1985; Kyrouli et al., 1990; Wyrwicka, 1992) . In fact, one of the most characteristic anatomical features of this structure is its reciprocal connections with the brainstem, namely the parabrachial area (de Olmos 1969 (de Olmos , 1972 Schwaber et al., 1982; Alheid et al., 1995) . The parabrachial area has been implicated in ingestive behavior as well (Takaki et al., 1990 , Wyrwicka 1992 ). The 5-HT 1B receptor mRNA found in the central amygdaloid complex may be in neurons projecting to the parabrachial area, which express the 5-HT 1B receptor protein (Bruinvels et al., 1994) . Via this innervation, ingestive behavior may be modulated.
In summary, by studying the effects of fenfluramine in 5-HT 1B knock-out mice, we have found that stimulation of this receptor is required for the anorectic action of this drug. We have also found that 5-HT 1B receptor stimulation is required for induction of c-fos in the PVN, CeA, and BNST, therefore suggesting a role of these regions in mediating fenfluramine-induced anorexia. Fi- Figure 7 . c-Fos induction in C eA and BNST by fenfluramine. Saline administration yielded no induction in either structure in wild type (A, D) . In response to fenfluramine, positively stained nuclei were seen in the C eA and BNST of wild types only (B, E) and were absent in knock-outs (C, F ). Wild types and knock-outs were indistinguishable after saline administration. Scale bar, 1 mm.
nally, we have shown that stimulation of 5-HT 1B receptors in wild-type mice with the direct agonist RU24969 is able to mimic both the anorectic and c-fos effects of fenfluramine. These results imply that 5-HT 1B agonists might be a therapeutic alternative to fenfluramine for the treatment of obesity. Importantly, this treatment may avoid the complications of pulmonary hypertension and mitral valve insufficiency that is seen with this general serotonin releaser and uptake inhibitor (Newman, 1997; Deitel, 1997) . With the recent surge in the development of 5-HT 1B -specific agonists for their anti-migraine properties (Schoenen, 1997) , this viable alternative may soon be within our reach.
